Clinical Scorecard: Impact of Pre-existing Comorbid Conditions on Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Study from the EBMT

At a Glance

Key Highlights

• The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) is adapted from Charlson index to predict NRM in allo-HCT patients.
• EBMT registry data from 2010-2018 was used to analyze the impact of pre-existing comorbidities on transplant outcomes.
• Comorbidities assessed include solid tumors, inflammatory bowel disease, diabetes, renal, hepatic, pulmonary, cardiac, cerebrovascular diseases, obesity, psychiatric disturbances, and others.

Guideline-Based Recommendations

Diagnosis

• Assess pre-existing comorbidities comprehensively using EBMT Med-A form prior to allo-HCT.
• Evaluate pulmonary function (DLCO, FEV1) to determine severity of pulmonary comorbidity.
• Use standardized criteria for grading acute and chronic GVHD post-transplant.

Management

• Incorporate comorbidity assessment into transplant risk stratification using HCT-CI.
• Optimize donor selection and conditioning regimens considering patient comorbidities.
• Apply in vivo T-cell depletion (e.g., anti-thymocyte globulin or alemtuzumab) as appropriate to reduce GVHD risk.

Monitoring & Follow-up

• Regular follow-up reporting to EBMT registry including comorbidity status and transplant outcomes.
• Monitor for infectious complications and GVHD severity post-transplant.
• Track non-relapse mortality and relapse incidence using competing risk analysis.

Risks

• Higher comorbidity burden is associated with increased non-relapse mortality.
• Pulmonary, hepatic, cardiac, and renal comorbidities significantly impact transplant outcomes.
• Infections requiring ongoing antimicrobial therapy post-transplant increase mortality risk.

Patient & Prescribing Data

Adults with hematologic malignancies undergoing first allo-HCT with available full comorbidity data

Improved donor selection and supportive care over time may reduce the impact of comorbidities on NRM; ongoing evaluation of HCT-CI predictive value is necessary.

Clinical Best Practices

• Ensure complete and accurate documentation of pre-existing comorbidities prior to allo-HCT.
• Use the HCT-CI score to guide individualized risk assessment and transplant decision-making.
• Maintain multidisciplinary care including transplant physicians, infectious disease specialists, and supportive care teams.
• Regularly update transplant protocols to reflect evolving evidence on comorbidity impact and management.

References

• European Society for Blood and Marrow Transplantation (EBMT) Registry
• Sorror et al., Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), 2005
• Glucksberg et al., Grading of acute GVHD
• Shulman et al., Classification of chronic GVHD